|Bid||28.25 x 200|
|Ask||28.45 x 1000|
|Day's Range||29.13 - 29.78|
|52 Week Range||18.03 - 32.50|
|PE Ratio (TTM)||59.55|
|Earnings Date||Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.00|
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EXEL. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $277 million.
Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the RBC Capital Markets Global Healthcare Conference taking place February 21-22 in New York, NY.
Exelixis (EXEl) announces positive data from a phase II trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma.
Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.
Exelixis, Inc. today announced results from a phase 2 investigator-sponsored trial of cabozantinib for the first-line treatment of metastatic radioiodine -refractory differentiated thyroid carcinoma .
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / U.S. markets rallied on Monday, after posting its worst weekly decline in two years, as President Trump unveiled details from his long awaited $200 billion ...
Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.
The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Exelixis, Inc. announced today that its fourth quarter and full year 2017 financial results will be released on Monday, February 26, 2018 after the markets close. At 5:00 p.m.
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EXEL. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $973 million.
Exelixis, Inc. today announced updated data from expansion cohorts in a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors.
Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at Leerink’s Global Healthcare Conference taking place February 14-15 in New York, NY.